Survey on the Treatment of Hypertension in Patients With Type 2 Diabetes
Launched by ASTRAZENECA · Dec 4, 2008
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Provision of written informed consent
- • Patient was diagnosed with type 2 diabetes
- • Patient is on antihypertensive treatments for at least 3 months, with the same regimen for a minimum of 4 weeks prior to survey
- Exclusion Criteria:
- • Patients are critically ill, had mental health problems or difficulty in communication
- • Patients who are unwilling or unable to provide informed consent
- • Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site).
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ho Chi Minh, , Vietnam
Hanoi, , Vietnam
Qui Nhon, Binh Dinh, Vietnam
Bien Hoa, Dong Nai, Vietnam
Thong Nhat, Dong Nai, Vietnam
Nha Trang, Khanh Hoa, Vietnam
Ca Mau, , Vietnam
Can Tho, , Vietnam
Nam Dinh, , Vietnam
Thai Binh, , Vietnam
Buon Me Thuoc, Dak Lak, Vietnam
Hue, Thua Thien, Vietnam
An Giang, , Vietnam
Bac Lieu, , Vietnam
Da Nang, , Vietnam
Dong Thap, , Vietnam
Hai Phong, , Vietnam
Kien Giang, , Vietnam
Tien Giang, , Vietnam
Patients applied
Trial Officials
Dang Van Phuoc, PhD.
Principal Investigator
University of Medicine and Pharmacy of HCMC
Pham Nguyen Vinh, PhD.
Principal Investigator
Tam Duc Heart Hospital
Pham Gia Khai, PhD.
Principal Investigator
Vietnam Heart Association
Nguyen Thy Khue, PhD
Principal Investigator
Endocrinology and Diabetes Association of HCMC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials